RxDoctor Payments Data

Henry Florez, MD

Internal Medicine · Yuma, AZNPI 1356446454

Payments from drug & device makers

$1,663in general payments, 2019–2025

Across 87 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$575
  • AstraZeneca$268
  • Novo Nordisk$210
  • Nestle Healthcare Nutrition Inc.$162
  • Amgen$151
  • Davol Inc.$81
  • plus $215 from 10 others

What the payments were for

  • Food & beverage$1,663100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,663 in reported general payments places this provider in the 80th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$82,192
Medicare patients
343
Services billed
1,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide90$154,892
JardianceEmpagliflozin79$129,199
JanuviaSitagliptin Phosphate120$115,851
OzempicSemaglutide69$96,856
EliquisApixaban70$87,109
FarxigaDapagliflozin Propanediol45$55,907
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog40$18,237
TradjentaLinagliptin14$15,316
EntrestoSacubitril/Valsartan11$12,074
TresibaInsulin Degludec11$9,896
Atorvastatin Calcium698$9,585
VascepaIcosapent Ethyl15$7,518
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$7,328
Liothyronine Sodium126$7,248
Repatha SureclickEvolocumab11$6,844

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$14$154,89290 claims
Boehringer IngelheimJardiance, Tradjenta$20$144,51593 claims
Novo NordiskOzempic, Tresiba, Levemir$210$109,62899 claims
AstraZenecaFarxiga$268$55,90745 claims
NovartisEntresto$17$12,07411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Yuma

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →